Thomas Van Looy

415 total citations
19 papers, 352 citations indexed

About

Thomas Van Looy is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Neurology. According to data from OpenAlex, Thomas Van Looy has authored 19 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Gastroenterology and 5 papers in Neurology. Recurrent topics in Thomas Van Looy's work include Gastrointestinal Tumor Research and Treatment (14 papers), Sarcoma Diagnosis and Treatment (13 papers) and Gastric Cancer Management and Outcomes (10 papers). Thomas Van Looy is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (14 papers), Sarcoma Diagnosis and Treatment (13 papers) and Gastric Cancer Management and Outcomes (10 papers). Thomas Van Looy collaborates with scholars based in Belgium, Switzerland and United States. Thomas Van Looy's co-authors include Patrick Schöffski, Agnieszka Woźniak, Maria Dêbiec‐Rychter, Raf Sciot, Jasmien Wellens, Giuseppe Floris, Haifu Li, Ulla Vanleeuw, Jonathan A. Fletcher and Jasmien Cornillie and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Thomas Van Looy

18 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Van Looy Belgium	10	233	201	95	85	70	19	352
Yemarshet K. Gebreyohannes Belgium	11	185 0.8×	131 0.7×	86 0.9×	66 0.8×	105 1.5×	22	322
Yoshito Komatsu Japan	11	264 1.1×	271 1.3×	98 1.0×	95 1.1×	66 0.9×	24	422
Yasunori Deguchi Japan	10	160 0.7×	34 0.2×	104 1.1×	42 0.5×	153 2.2×	16	352
Rie Nakatsuka Japan	9	71 0.3×	46 0.2×	76 0.8×	13 0.2×	86 1.2×	21	240
Weicai Huang China	9	231 1.0×	65 0.3×	58 0.6×	6 0.1×	142 2.0×	12	356
Elizabeth Hall–Meyers United States	5	54 0.2×	56 0.3×	133 1.4×	19 0.2×	49 0.7×	6	313
Stefan Paul Moenig Germany	9	102 0.4×	24 0.1×	90 0.9×	28 0.3×	143 2.0×	21	300
Jian-Xian Lin China	11	211 0.9×	102 0.5×	96 1.0×	4 0.0×	107 1.5×	47	385
Taro Isobe Japan	10	195 0.8×	37 0.2×	72 0.8×	5 0.1×	139 2.0×	31	345
Norihisa Uemura Japan	13	282 1.2×	13 0.1×	93 1.0×	31 0.4×	132 1.9×	45	502

Countries citing papers authored by Thomas Van Looy

Since Specialization

Citations

This map shows the geographic impact of Thomas Van Looy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Van Looy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Van Looy more than expected).

Fields of papers citing papers by Thomas Van Looy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Van Looy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Van Looy. The network helps show where Thomas Van Looy may publish in the future.

Co-authorship network of co-authors of Thomas Van Looy

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Van Looy. A scholar is included among the top collaborators of Thomas Van Looy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Van Looy. Thomas Van Looy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Schöffski, Patrick, Yemarshet K. Gebreyohannes, Thomas Van Looy, et al.. (2022). In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. Biomedicines. 10(5). 1135–1135. 5 indexed citations

Remmerie, Bart, Thomas Van Looy, Sarah Rusch, et al.. (2019). Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor. Advances in Therapy. 37(1). 578–591. 2 indexed citations

Gebreyohannes, Yemarshet K., Patrick Schöffski, Thomas Van Looy, et al.. (2016). Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations. Molecular Cancer Therapeutics. 15(12). 2845–2852. 29 indexed citations

Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2015). Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Translational Oncology. 8(2). 112–118. 13 indexed citations

Woźniak, Agnieszka, Thomas Van Looy, Giuseppe Floris, et al.. (2015). Abstract 1461: A panel of patient derived gastrointestinal stromal tumors (GIST) xenograft models for in vivo preclinical drug testing. Cancer Research. 75(15_Supplement). 1461–1461. 1 indexed citations

Gebreyohannes, Yemarshet K., Agnieszka Woźniak, Thomas Van Looy, et al.. (2015). PLX9486 shows anti-tumor efficacy in a patient-derived gastrointestinal stromal tumor (GIST) xenograft model resistant to standard tyrosine kinase inhibitors (TKI). 1 indexed citations

Li, Haifu, Jasmien Cornillie, Agnieszka Woźniak, et al.. (2015). Abstract 1460: Establishment and characterization of a panel of patient-derived soft tissue sarcoma (STS) xenograft models for in vivo testing of novel therapeutic approaches. Cancer Research. 75(15_Supplement). 1460–1460. 21 indexed citations

Cornillie, Jasmien, Agnieszka Woźniak, Haifu Li, et al.. (2015). Abstract 5353: Efficacy of an innovative, enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenograft models. Cancer Research. 75(15_Supplement). 5353–5353. 1 indexed citations

Gebreyohannes, Yemarshet K., Thomas Van Looy, Agnieszka Woźniak, et al.. (2015). Abstract 775: Anti-tumor effects of dovitinib, a multi-target kinase inhibitor, in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. Cancer Research. 75(15_Supplement). 775–775. 3 indexed citations

10.

Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2014). Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research. 20(23). 6071–6082. 42 indexed citations

11.

Li, Haifu, Agnieszka Woźniak, Raf Sciot, et al.. (2014). Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. Translational Oncology. 7(6). 665–671. 36 indexed citations

12.

Looy, Thomas Van, Yemarshet K. Gebreyohannes, Agnieszka Woźniak, et al.. (2014). Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. PubMed. 4(1). 10–10. 22 indexed citations

13.

Woźniak, Agnieszka, Barbara Dewaele, Giuseppe Floris, et al.. (2014). Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Modern Pathology. 27(11). 1510–1520. 23 indexed citations

14.

Li, Haifu, Agnieszka Woźniak, Thomas Van Looy, et al.. (2013). Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS).. Journal of Clinical Oncology. 31(15_suppl). e13528–e13528. 1 indexed citations

15.

Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2012). The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. Molecular Cancer Therapeutics. 11(8). 1799–1808. 49 indexed citations

16.

Floris, Giuseppe, Agnieszka Woźniak, Raf Sciot, et al.. (2012). A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research. 19(3). 620–630. 59 indexed citations

17.

Looy, Thomas Van, Agnieszka Woźniak, Raf Sciot, et al.. (2012). Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models.. Journal of Clinical Oncology. 30(15_suppl). 10030–10030. 3 indexed citations

18.

Floris, Giuseppe, Raf Sciot, Agnieszka Woźniak, et al.. (2011). The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research. 17(17). 5604–5614. 41 indexed citations

19.

Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2011). Abstract A217: The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models.. Molecular Cancer Therapeutics. 10(11_Supplement). A217–A217.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact